Company intelligence / Profile preview

PreludeDx

Laguna Hills, California, United Statespreludedx.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s lead product, DCISionRT, has been clinically validated across multiple cohorts and published studies to predict recurrence risk and radiation therapy benefit for women with ductal carcinoma in situ after breast-conserving surgery. It enables personalized treatment decisions by identifying patients who may safely omit radiation or require intensified therapy. The test has received Advanced Diagnostic Laboratory Test status from CMS and broadening access through managed care agreements.

Therapeutic areas: Oncology
Modalities: Diagnostic test (molecular diagnostics)Biomarker-based assay
Industry: Molecular Diagnostics

Drug pipeline

1 asset

DCISionRT

Commercial

Indications: Ductal carcinoma in situ (DCIS), Early-stage breast cancer

Partnerships

Medical Cost Containment Professionals LLC (managed care provider agreement)

Beyond the preview

Go deeper on PreludeDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PreludeDx.

Explore the full profile